• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

评估 BRCA1 和 BRCA2 作为免疫检查点抑制剂反应的指标。

Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.

机构信息

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City.

出版信息

JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.

DOI:10.1001/jamanetworkopen.2021.7728
PMID:33961040
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8105747/
Abstract

This cohort study examines the association of and with tumor mutation burden and response to immune checkpoint inhibitors.

摘要

本队列研究探讨了 和 与肿瘤突变负担以及对免疫检查点抑制剂反应的关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b666/8105747/f45e64dd18c3/jamanetwopen-e217728-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b666/8105747/1c85f83229e7/jamanetwopen-e217728-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b666/8105747/f45e64dd18c3/jamanetwopen-e217728-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b666/8105747/1c85f83229e7/jamanetwopen-e217728-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b666/8105747/f45e64dd18c3/jamanetwopen-e217728-g002.jpg

相似文献

1
Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.评估 BRCA1 和 BRCA2 作为免疫检查点抑制剂反应的指标。
JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.
2
Talazoparib for BRCA-mutated advanced breast cancer.他拉唑帕尼用于治疗携带BRCA基因突变的晚期乳腺癌。
Lancet Oncol. 2018 Oct;19(10):e511. doi: 10.1016/S1470-2045(18)30650-8. Epub 2018 Aug 23.
3
Lurbinectedin for BRCA-mutated advanced breast cancer.鲁比卡丁用于治疗携带BRCA基因突变的晚期乳腺癌。
Lancet Oncol. 2018 Nov;19(11):e582. doi: 10.1016/S1470-2045(18)30737-X. Epub 2018 Sep 27.
4
BRCA1 and BRCA2 Testing Among Young Breast Cancer Survivors.年轻乳腺癌幸存者中的BRCA1和BRCA2检测
JAMA Oncol. 2016 May 1;2(5):688-9. doi: 10.1001/jamaoncol.2016.0976.
5
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.BRCA1 和 BRCA2 基因突变携带者乳腺癌术后卵巢切除术对生存的影响。
JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.
6
BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.BRCA1/2 信号通路与乳腺癌和卵巢癌同源重组缺陷
Future Oncol. 2021 Jul;17(21):2817-2830. doi: 10.2217/fon-2021-0072. Epub 2021 Jun 1.
7
Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.土耳其乳腺癌患者BRCA1/2突变的临床病理特征及遗传特性
Cancer Genet. 2020 Jan;240:23-32. doi: 10.1016/j.cancergen.2019.10.004. Epub 2019 Oct 16.
8
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.DNA损伤反应标志物在BRCA突变的乳腺癌中差异表达。
Breast Cancer Res Treat. 2015 Feb;150(1):81-90. doi: 10.1007/s10549-015-3306-6. Epub 2015 Feb 19.
9
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.BRCA1 和 BRCA2 家族乳腺癌、卵巢癌和对侧乳腺癌的外显率：老年时癌症发病率高。
Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4.
10
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.一项针对BRCA1或BRCA2突变的HER2阴性晚期乳腺癌一线治疗的I期试验，随后进行两个周期卡铂-奥拉帕利联合治疗，然后奥拉帕利单药治疗与卡培他滨对比的随机II期试验（REVIVAL）：一项随机对照试验的研究方案。
Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0.

引用本文的文献

1
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.多组学分析揭示了晚期不可切除胆管癌化学免疫治疗疗效和预后的预测生物标志物。
BMC Med. 2025 Jul 22;23(1):435. doi: 10.1186/s12916-025-04263-z.
2
Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy.评估铁死亡作为预测癌症免疫治疗疗效的生物标志物
Cancer Res Commun. 2025 Aug 1;5(8):1288-1297. doi: 10.1158/2767-9764.CRC-25-0268.
3
The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer.

本文引用的文献

1
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.奥拉帕利联合度伐利尤单抗治疗种系 BRCA 突变转移性乳腺癌患者（MEDIOLA）：一项开放标签、多中心、1/2 期、篮子研究。
Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6.
2
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.尼拉帕利联合帕博利珠单抗治疗晚期或转移性三阴性乳腺癌的开放标签临床试验。
JAMA Oncol. 2019 Aug 1;5(8):1132-1140. doi: 10.1001/jamaoncol.2019.1029.
3
胰腺癌中DNA修复与免疫微环境之间的相互作用
Biomedicines. 2025 Apr 24;13(5):1031. doi: 10.3390/biomedicines13051031.
4
Targeting amino acid metabolism to inhibit gastric cancer progression and promote anti-tumor immunity: a review.靶向氨基酸代谢以抑制胃癌进展并促进抗肿瘤免疫：综述
Front Immunol. 2025 Feb 13;16:1508730. doi: 10.3389/fimmu.2025.1508730. eCollection 2025.
5
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab.非小细胞肺癌患者中程序性死亡配体1表达为高（50%-89%）与非常高（≥90%）的患者接受一线帕博利珠单抗或西米普利单抗治疗的三年总生存结果及相关分析
JTO Clin Res Rep. 2024 Apr 12;5(9):100675. doi: 10.1016/j.jtocrr.2024.100675. eCollection 2024 Sep.
6
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors.结直肠癌中 DNA 修复依赖性免疫原性缺陷：错误带来的机会。
Br J Cancer. 2024 Nov;131(10):1576-1590. doi: 10.1038/s41416-024-02848-8. Epub 2024 Sep 13.
7
Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future.用于对抗癌症的治疗性细菌和病毒：癌症治疗中的双刃剑：对未来的新见解
Cell Commun Signal. 2024 Apr 24;22(1):239. doi: 10.1186/s12964-024-01622-w.
8
Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma.不同食管鳞状细胞癌患者的 PD-L1 表达的分子特征。
Cancer Biol Ther. 2023 Dec 31;24(1):2256927. doi: 10.1080/15384047.2023.2256927. Epub 2023 Sep 21.
9
Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor.携带种系 BRCA2 p.I3169M fs*48 变异的胰腺癌对铂类药物和 PARP 抑制剂的临床反应。
Jpn J Clin Oncol. 2024 Feb 7;54(2):201-205. doi: 10.1093/jjco/hyad157.
10
Management of PALB2-associated breast cancer: A literature review and case report.PALB2相关乳腺癌的管理：文献综述与病例报告
Clin Case Rep. 2023 Aug 22;11(8):e7747. doi: 10.1002/ccr3.7747. eCollection 2023 Aug.
A C-X-C Chemokine Receptor Type 2-Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis.
C-X-C 趋化因子受体 2 介导的肿瘤细胞与巨噬细胞间的串扰促进胃癌转移。
Clin Cancer Res. 2019 Jun 1;25(11):3317-3328. doi: 10.1158/1078-0432.CCR-18-3567. Epub 2019 Feb 22.
4
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.肿瘤突变负荷可预测多种癌症类型免疫治疗后的生存情况。
Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.
5
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.CXCR2抑制可显著抑制胰腺导管腺癌的转移并增强免疫治疗效果。
Cancer Cell. 2016 Jun 13;29(6):832-845. doi: 10.1016/j.ccell.2016.04.014. Epub 2016 Jun 2.
6
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.cBio 癌症基因组学门户：一个用于探索多维癌症基因组学数据的开放平台。
Cancer Discov. 2012 May;2(5):401-4. doi: 10.1158/2159-8290.CD-12-0095.